Stemline's SL-401 meets in Phase II for BPDCN

Stemline Therapeutics Inc. (NASDAQ:STML) said SL-401 met the primary endpoint in a pivotal Phase II trial to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN), a form of acute myelogenous leukemia (AML). The company plans to begin submission of a BLA to

Read the full 411 word article

User Sign In